Raajit K. Rampal, MD, PhD

Articles

Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials

February 14th 2025

Panelists discuss how they select personalized therapy for patients with myelofibrosis (MF) based on current data, considering factors such as disease characteristics and patient-specific factors.

Treatment Goals for Myelofibrosis

February 14th 2025

Panelists discuss their overall treatment goals for myelofibrosis (MF), the role of transplant within their practice, and the benefits and challenges associated with transplantation, as well as how they determine which patients are best suited for this approach.

An Overview to Myelofibrosis and Disease Risk

February 7th 2025

Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.

Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024

February 7th 2025

Panelists discuss noteworthy updates in polycythemia vera (PV) from ASH 2024, explore the future of PV treatment, highlight the greatest unmet needs, and discuss how ongoing investigational therapies aim to address these gaps. They also share clinical pearls for community oncologists in managing PV.

Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

February 3rd 2025

Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.

Interferon Real- World Treatment Patterns in PV

February 3rd 2025

Panelists discuss real-world treatment patterns for ropeginterferon alfa-2b (Ropeg alfa-2b) in the management of polycythemia vera (PV).

Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

January 24th 2025

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Safety Considerations for PV Therapy

January 24th 2025

Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.

Interferon Therapy in PV

January 17th 2025

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

JAK Inhibition in Polycythemia Vera: Treatment Updates

January 17th 2025

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.

Cytoreductive Therapy in PV Treatment Paradigm

January 2nd 2025

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.

Initial Treatment Strategies for Polycythemia Vera

December 23rd 2024

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.

Emerging Treatments for Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.

Individualizing Therapy Goals for Patients With Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, emphasizes the importance of individualizing therapy for patients with myelofibrosis, focusing on improving quality of life and addressing specific issues like anemia and spleen volume, with the understanding that these treatments are palliative and goals should be revisited regularly.

Selection and Sequencing of JAK Inhibitors for Patients With MF

April 3rd 2024

Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.

The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

April 3rd 2024

Andrew Kuykendall, MD, discusses the efficacy and adverse effects of fedratinib, highlighting its potential in the second-line setting for patients resistant to ruxolitinib, with updates from FREEDOM-2 emphasizing manageable gastrointestinal tolerability concerns.

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

March 27th 2024

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.

Future Directions in Combination Therapies for Myelofibrosis

March 27th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.

Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

March 20th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss luspatercept with or without ruxolitinib for the treatment of anemia in patients with myelofibrosis. The combination has demonstrated promise in reducing transfusion dependency, as seen in data from ACE-536-MF-001, with ongoing phase 3 trials.

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

March 20th 2024

Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.